Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02710396
Title Genetic Predictors of Benefit to Pembrolizumab
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Columbia University New York New York 10032 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field